Inti.Pk

INTI.PK has a negative equity position of -$1,291,910, indicating a significant deficit in its capital structure. The company's liquidity is supported by $2,375,490 in cash and equivalents, which is a positive sign given its current ratio of 3.19. However, the company's operating cash flow is negative at -$3,231,370, suggesting ongoing operational challenges.

The company's profitability is weak, with a net loss of -$3,300,340 and an operating loss of -$3,426,650. The return on equity is 2.55, which is unusually high given the negative equity, and the return on assets is -1.31, indicating poor asset utilization. These metrics are below the typical performance for the biotechnology industry.

INTI.PK does not provide segment or geographic revenue data in the available financial reports, making it difficult to assess revenue concentration or geographic exposure. The lack of detailed segment reporting is a limitation in understanding the company's operational diversification.

The company's growth trajectory is uncertain, with no revenue reported and a net loss in the latest financial period. The absence of revenue and the continued losses suggest a lack of commercialization or market traction. The company's future performance will depend on its ability to generate revenue and reduce its operating losses.

The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the company's negative equity and operating cash flow suggest potential long-term liquidity challenges. The dilution potential is low, but the company's financial position may require additional capital in the future.

Recent events and filings do not provide specific details on the company's operations or strategic initiatives. The lack of recent financial activity or significant events makes it challenging to assess the company's current direction and strategic focus.